Cargando…

Dose–Response Meta-Analysis of Corticosteroid Effects in SARS Outbreak: A Model for Risk Stratification and Screening Strategy for Osteonecrosis of Femoral Head Post-Corticosteroid Therapy for COVID-19

Corticosteroids (CS) have been used in the management regimens for COVID-19 disease to mitigate the cytokine storm and ill effects of the pulmonary inflammatory cascade. With the rampant use of CS, clinicians started reporting the occurrence of osteonecrosis of the femoral head (OFH). In this system...

Descripción completa

Detalles Bibliográficos
Autores principales: Muthu, Sathish, Jeyaraman, Madhan, Selvaraj, Preethi, Jeyaraman, Naveen, Potty, Anish G., Gupta, Ashim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10143798/
https://www.ncbi.nlm.nih.gov/pubmed/37109436
http://dx.doi.org/10.3390/life13040907
_version_ 1785033943282614272
author Muthu, Sathish
Jeyaraman, Madhan
Selvaraj, Preethi
Jeyaraman, Naveen
Potty, Anish G.
Gupta, Ashim
author_facet Muthu, Sathish
Jeyaraman, Madhan
Selvaraj, Preethi
Jeyaraman, Naveen
Potty, Anish G.
Gupta, Ashim
author_sort Muthu, Sathish
collection PubMed
description Corticosteroids (CS) have been used in the management regimens for COVID-19 disease to mitigate the cytokine storm and ill effects of the pulmonary inflammatory cascade. With the rampant use of CS, clinicians started reporting the occurrence of osteonecrosis of the femoral head (OFH). In this systematic review, we aim to analyze the literature and identify the definitive cumulative dose and duration of CS needed for the development of OFH based on the SARS model and generate a risk-based screening recommendation for OFH in convalescent COVID-19 patients to facilitate early identification and management. An electronic database search was conducted until December 2022 in PubMed, Web of Science, Embase, and CNKI (China Knowledge Resource Integrated Database). Studies involving CS therapy and osteonecrosis data in SARS patients were included. Three authors independently extracted the data from the included studies and a dose–response meta-analysis was performed for various doses and duration of CS utilized in the included studies. We selected 12 articles with 1728 patients in the analysis. The mean age was 33.41 (±4.93) years. The mean dosage of CS administered was 4.64 (±4.7) g which was administered for a mean duration of 29.91 (±12.3) days. The risk of osteonecrosis increases at pooled OR of 1.16 (95% CI 1.09–1.23, p < 0.001) per 2.0 g increase in the cumulative dose of CS usage. Similarly, the risk increases at pooled OR of 1.02 (95% CI 1.01–1.03, p < 0.001) per 5 days of increase in the cumulative duration of CS usage. A cumulative dosage of 4 g and a duration of 15 days were determined as the critical cut-off for the non-linear dose–response relationship observed. Appropriate and frequent screening of these individuals at regular intervals would help in the identification of the disease at an early stage in order to treat them appropriately.
format Online
Article
Text
id pubmed-10143798
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-101437982023-04-29 Dose–Response Meta-Analysis of Corticosteroid Effects in SARS Outbreak: A Model for Risk Stratification and Screening Strategy for Osteonecrosis of Femoral Head Post-Corticosteroid Therapy for COVID-19 Muthu, Sathish Jeyaraman, Madhan Selvaraj, Preethi Jeyaraman, Naveen Potty, Anish G. Gupta, Ashim Life (Basel) Systematic Review Corticosteroids (CS) have been used in the management regimens for COVID-19 disease to mitigate the cytokine storm and ill effects of the pulmonary inflammatory cascade. With the rampant use of CS, clinicians started reporting the occurrence of osteonecrosis of the femoral head (OFH). In this systematic review, we aim to analyze the literature and identify the definitive cumulative dose and duration of CS needed for the development of OFH based on the SARS model and generate a risk-based screening recommendation for OFH in convalescent COVID-19 patients to facilitate early identification and management. An electronic database search was conducted until December 2022 in PubMed, Web of Science, Embase, and CNKI (China Knowledge Resource Integrated Database). Studies involving CS therapy and osteonecrosis data in SARS patients were included. Three authors independently extracted the data from the included studies and a dose–response meta-analysis was performed for various doses and duration of CS utilized in the included studies. We selected 12 articles with 1728 patients in the analysis. The mean age was 33.41 (±4.93) years. The mean dosage of CS administered was 4.64 (±4.7) g which was administered for a mean duration of 29.91 (±12.3) days. The risk of osteonecrosis increases at pooled OR of 1.16 (95% CI 1.09–1.23, p < 0.001) per 2.0 g increase in the cumulative dose of CS usage. Similarly, the risk increases at pooled OR of 1.02 (95% CI 1.01–1.03, p < 0.001) per 5 days of increase in the cumulative duration of CS usage. A cumulative dosage of 4 g and a duration of 15 days were determined as the critical cut-off for the non-linear dose–response relationship observed. Appropriate and frequent screening of these individuals at regular intervals would help in the identification of the disease at an early stage in order to treat them appropriately. MDPI 2023-03-29 /pmc/articles/PMC10143798/ /pubmed/37109436 http://dx.doi.org/10.3390/life13040907 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Systematic Review
Muthu, Sathish
Jeyaraman, Madhan
Selvaraj, Preethi
Jeyaraman, Naveen
Potty, Anish G.
Gupta, Ashim
Dose–Response Meta-Analysis of Corticosteroid Effects in SARS Outbreak: A Model for Risk Stratification and Screening Strategy for Osteonecrosis of Femoral Head Post-Corticosteroid Therapy for COVID-19
title Dose–Response Meta-Analysis of Corticosteroid Effects in SARS Outbreak: A Model for Risk Stratification and Screening Strategy for Osteonecrosis of Femoral Head Post-Corticosteroid Therapy for COVID-19
title_full Dose–Response Meta-Analysis of Corticosteroid Effects in SARS Outbreak: A Model for Risk Stratification and Screening Strategy for Osteonecrosis of Femoral Head Post-Corticosteroid Therapy for COVID-19
title_fullStr Dose–Response Meta-Analysis of Corticosteroid Effects in SARS Outbreak: A Model for Risk Stratification and Screening Strategy for Osteonecrosis of Femoral Head Post-Corticosteroid Therapy for COVID-19
title_full_unstemmed Dose–Response Meta-Analysis of Corticosteroid Effects in SARS Outbreak: A Model for Risk Stratification and Screening Strategy for Osteonecrosis of Femoral Head Post-Corticosteroid Therapy for COVID-19
title_short Dose–Response Meta-Analysis of Corticosteroid Effects in SARS Outbreak: A Model for Risk Stratification and Screening Strategy for Osteonecrosis of Femoral Head Post-Corticosteroid Therapy for COVID-19
title_sort dose–response meta-analysis of corticosteroid effects in sars outbreak: a model for risk stratification and screening strategy for osteonecrosis of femoral head post-corticosteroid therapy for covid-19
topic Systematic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10143798/
https://www.ncbi.nlm.nih.gov/pubmed/37109436
http://dx.doi.org/10.3390/life13040907
work_keys_str_mv AT muthusathish doseresponsemetaanalysisofcorticosteroideffectsinsarsoutbreakamodelforriskstratificationandscreeningstrategyforosteonecrosisoffemoralheadpostcorticosteroidtherapyforcovid19
AT jeyaramanmadhan doseresponsemetaanalysisofcorticosteroideffectsinsarsoutbreakamodelforriskstratificationandscreeningstrategyforosteonecrosisoffemoralheadpostcorticosteroidtherapyforcovid19
AT selvarajpreethi doseresponsemetaanalysisofcorticosteroideffectsinsarsoutbreakamodelforriskstratificationandscreeningstrategyforosteonecrosisoffemoralheadpostcorticosteroidtherapyforcovid19
AT jeyaramannaveen doseresponsemetaanalysisofcorticosteroideffectsinsarsoutbreakamodelforriskstratificationandscreeningstrategyforosteonecrosisoffemoralheadpostcorticosteroidtherapyforcovid19
AT pottyanishg doseresponsemetaanalysisofcorticosteroideffectsinsarsoutbreakamodelforriskstratificationandscreeningstrategyforosteonecrosisoffemoralheadpostcorticosteroidtherapyforcovid19
AT guptaashim doseresponsemetaanalysisofcorticosteroideffectsinsarsoutbreakamodelforriskstratificationandscreeningstrategyforosteonecrosisoffemoralheadpostcorticosteroidtherapyforcovid19